γ-Secretase

ELN318463 is a selective inhibitor of γ-secretase, targeting the amyloid precursor protein (APP). It demonstrates differential inhibition of presenilin 1 (PS1) and presenilin 2 (PS2) γ-secretase complexes, with EC50 values of 12 nM and 656 nM, respectively, showcasing a 51-fold greater selectivity for PS1. This compound is primarily utilized in research focused on Alzheimer's disease and related neurodegenerative disorders, making it a valuable tool for studies investigating APP processing and amyloid plaque formation.

(-)-FRM-024 is a potent γ-secretase modulator that effectively penetrates the central nervous system. This compound is instrumental in Alzheimer’s disease research, facilitating the study of amyloid precursor protein processing and its implications in neurodegeneration. Its ability to modulate γ-secretase activity makes it a valuable tool for exploring therapeutic interventions in Alzheimer's pathology.

γ-Secretase modulator 4 is a potent modulator of the γ-secretase enzyme, characterized by its ability to effectively reduce Aβ42 peptide levels with IC50 values of 0.014 μM in human samples and 0.017 μM in mouse samples. This compound has significant implications in Alzheimer's research, particularly in the study of amyloid-beta production and the related pathophysiology. Its mechanism of action makes it a valuable tool for investigations into therapeutic strategies targeting Alzheimer's disease.

(9R)-RO7185876 is a selective inhibitor of γ-secretase, targeting the cleavage of amyloid precursor protein. This compound significantly reduces the secretion of Aβ42 peptides, making it a valuable tool for research on Alzheimer's disease and related disorders, such as cerebral amyloid angiopathy and multi-infarct dementia. Additionally, (9R)-RO7185876 may be utilized to investigate conditions associated with amyloid deposition, including dementia pugilistica and Down syndrome.

Gamma-Secretase Modulator 1 Hydrochloride acts as a modulator of gamma-secretase, a crucial enzyme implicated in the pathogenesis of Alzheimer's disease. This compound is designed to influence the processing of amyloid precursor protein (APP), ultimately affecting the production of amyloid-beta peptide. Its potential applications include studying the modulation of amyloid-beta levels and investigating therapeutic strategies for Alzheimer's disease and related neurodegenerative disorders.

Nivegacetor is a potent γ-secretase modulator that plays a critical role in the modulation of amyloid precursor protein processing. By influencing the activity of γ-secretase, Nivegacetor is valuable for research into Alzheimer's disease and other neurodegenerative conditions. Its ability to alter the production of amyloid-beta peptides makes it a useful tool for exploring therapeutic pathways and understanding the molecular mechanisms underlying these diseases.

Aβ42-IN-1 is a potent γ-secretase modulator (GSM) designed to target the enzymatic cleavage of amyloid precursor protein, effectively lowering amyloid-beta 42 (Aβ42) levels. With an IC50 value of 0.091 μM, Aβ42-IN-1 demonstrates significant inhibition of Aβ42 production while avoiding CYP3A4 inhibition, indicating a favorable safety profile. Its sustained pharmacokinetic properties make it a valuable tool for research into Alzheimer's disease and related neuropathologies. This compound holds promise for exploring therapeutic strategies aimed at modulating γ-secretase activity in neurodegenerative disorders.

Aβ42-IN-1 free base is a potent γ-secretase modulator that exhibits high oral bioavailability and significant brain penetration. This compound effectively lowers Aβ42 levels with an IC50 of 0.091 μM, demonstrating substantial reduction of brain Aβ42 levels in murine models. Aβ42-IN-1 free base holds considerable potential for therapeutic applications in Alzheimer's disease research.

MK-0752 sodium is a potent, orally bioavailable inhibitor of γ-secretase, exhibiting a dose-dependent reduction of Aβ40 with an IC50 of 5 nM in human SH-SY5Y cells. This compound effectively crosses the blood-brain barrier and demonstrates the ability to decrease newly generated central nervous system Aβ levels in vivo. MK-0752 sodium is primarily utilized in research on Alzheimer’s disease and other neurodegenerative disorders linked to amyloid-beta pathology.

γ-Secretase modulator 10 is a selective modulator of the γ-secretase enzyme complex. It influences the cleavage of amyloid precursor protein (APP), thereby altering the production of amyloid β peptides associated with Alzheimer's disease pathogenesis. This compound is valuable for research applications focused on neurodegenerative diseases and therapeutic strategies aimed at modulating γ-secretase activity.

γ-Secretase modulator 14 is a selective modulator of the γ-secretase complex, influencing the cleavage of amyloid precursor protein (APP). This compound exhibits potential in Alzheimer's disease research by altering the production of amyloid-beta peptides. Its utility extends to investigating the mechanisms underlying neurodegenerative disorders and developing novel therapeutic strategies aimed at modulating γ-secretase activity.

γ-Secretase modulator 11 functions as a potent γ-secretase inhibitor, effectively reducing levels of amyloid beta 42 in vitro and demonstrating significant brain penetration. This compound exhibits minimal inhibition of cytochrome P450 enzymes, highlighting its selective profile. Additionally, γ-secretase modulator 11 has shown considerable efficacy in alleviating cognitive deficits in Alzheimer's disease model mice, making it a valuable tool for research in neurodegenerative disorders.

BPN-15606 besylate is a potent orally active γ-secretase modulator (GSM) that effectively reduces the production of Aβ42 and Aβ40 peptides in SHSY5Y neuroblastoma cells, exhibiting IC50 values of 7 nM and 17 nM, respectively. This compound has demonstrated the ability to lower Aβ42 and Aβ40 levels in the central nervous system of rodent models. Additionally, BPN-15606 besylate features favorable pharmacokinetic and pharmacodynamic properties, including good bioavailability, optimal half-life, and manageable clearance rates, making it valuable for Alzheimer's disease research and neurodegenerative studies.

BMS-932481 is a potent γ-secretase modulator that demonstrates selective reduction of β-amyloid peptides Aβ1-42 and Aβ1-40, exhibiting IC50 values of 6.6 nM and 25.3 nM, respectively. This compound is valuable for research into Alzheimer's disease and mechanisms of amyloid plaque formation, offering insights into potential therapeutic strategies targeting γ-secretase activity.

GSI-18 is a potent γ-secretase inhibitor that disrupts Notch signaling, contributing to its anticancer properties. This compound effectively inhibits the attachment-free growth of pancreatic cancer cells, making it valuable for research into cancer biology and therapeutic interventions. Its mechanism of action offers insights into the regulation of cell proliferation and differentiation in oncogenic contexts.

ELND 007 is a selective γ-secretase inhibitor that primarily targets the reduction of amyloid beta (Aβ) generation while minimizing inhibition of Notch signaling. It demonstrates significant biological activity in both in vitro and in vivo settings, effectively decreasing Aβ levels. This compound has shown potential therapeutic benefits for Alzheimer’s disease, particularly as evidenced by reductions in Aβ levels observed in cerebrospinal fluid during human clinical trials, following a strategic emphasis on metabolic stability and chirality in its development.

γ-Secretase-IN-2 is a potent inhibitor of γ-secretase, demonstrating an IC50 of 0.06 nM. This compound is instrumental in researching Alzheimer's disease, providing insights into the enzymatic processes involved in neurodegeneration. Its high efficacy makes it a valuable tool for studying the pathophysiology of Alzheimer's and exploring potential therapeutic strategies.

LY3056480 is a potent γ-secretase inhibitor that targets Notch signaling pathways. This compound has demonstrated efficacy in enhancing recovery from mild to moderate sensorineural hearing loss, while exhibiting a favorable safety profile. Additionally, intratympanic administration of LY3056480 has been shown to promote hair cell regeneration and contribute to partial auditory recovery in mammalian models, making it a valuable tool for research in hearing restoration and neurodegenerative studies.

γ-Secretase modulator 12 is a selective modulator of γ-secretase, specifically designed to reduce levels of amyloid-β42 (Aβ42) with an IC50 of 0.39 µM. This compound is valuable for investigating Alzheimer's disease mechanisms and potential therapeutic interventions. Additionally, γ-secretase modulator 12 demonstrates favorable pharmacokinetics with a good brain-to-plasma ratio (Kp, brain = 0.72) in murine models, making it suitable for in vivo studies.

γ-Secretase modulator 11 hydrochloride is a potent modulator of γ-secretase with an IC50 of 0.029 µM, demonstrating oral bioavailability. It effectively reduces brain Aβ42 levels, a critical factor in Alzheimer's disease pathology. Furthermore, this compound has shown the capability to improve cognitive deficits in Alzheimer's disease model mice, making it valuable for research into therapeutic strategies targeting Alzheimer's disease.

III-31-C is a hydroxyethyl urea-based inhibitor of γ-secretase. It demonstrates potent inhibition of amyloid-beta (Aβ) production, with an IC50 value of 10 nM in a cell-free γ-secretase assay and 200 nM in APP-transfected cells. This compound is relevant for research focused on Alzheimer's disease and offers valuable insights into the modulation of Aβ metabolism.

BMS-869780 is an orally active γ-secretase modulator that selectively regulates γ-secretase activity to modify the production profile of β-amyloid proteins. It alters the relative levels of specific β-amyloid subtypes while not inhibiting the overall production of β-amyloid proteins. Additionally, BMS-869780 demonstrates a synergistic effect when used in combination with acidic γ-secretase modulators, resulting in a reduction of total β-amyloid production in cell cultures. This compound is valuable for research into Alzheimer’s disease and related neurodegenerative disorders.

PF-06442609 is an orally active γ secretase modulator that effectively inhibits amyloid-beta (Aβ42) production with an IC50 of 6 nM. This compound demonstrates excellent brain penetration, making it suitable for research in neurodegenerative disease models, particularly Alzheimer's disease. Its modulatory effects on γ secretase activity provide valuable insights into the mechanistic understanding of amyloid plaque formation and associated pathologies.

LY-411575 (isomer 2) is a potent inhibitor of γ-secretase, an enzyme involved in the cleavage of amyloid precursor protein and a key player in the pathogenesis of Alzheimer's disease. This compound has been shown to effectively reduce the production of amyloid-beta peptides, making it valuable for research into therapeutic strategies for neurodegenerative disorders. Its selective inhibition of γ-secretase also facilitates the study of its role in cellular signaling and development.

GSI-136 is a potent inhibitor of γ-secretase, exhibiting an IC50 of 3 nM. This compound effectively reduces Aβ40 levels in diethylamine-extracted brain homogenates from C57BL/6 mice in a dose-dependent manner. GSI-136 serves as a valuable tool in medicinal chemistry and Alzheimer’s disease research, aiding in the exploration of therapeutic strategies targeting amyloid-beta production.

LY-411575 (isomer 1) is a potent γ-secretase inhibitor that selectively modulates the enzyme's activity. This compound is primarily utilized in the investigation of Alzheimer’s disease pathogenesis by reducing the production of harmful amyloid-beta peptides. Its mechanism of action allows for a deeper understanding of γ-secretase's role in cellular signaling and pathology, making it a valuable tool in neurological research.

LY-411575 (isomer 3) is a potent inhibitor of γ-secretase, an enzyme complex involved in the proteolytic processing of various transmembrane proteins, including amyloid precursor protein (APP). This compound is utilized in research studying Alzheimer's disease and other conditions associated with aberrant Notch signaling. Its ability to modulate γ-secretase activity makes it a valuable tool for investigating the therapeutic potential of targeting this pathway.

ELN318463 racemate is a selective γ-secretase inhibitor targeting the amyloid precursor protein (APP). It demonstrates differential inhibition of presenilin (PS1) and PS2-comprised γ-secretase, with EC50 values of 12 nM for PS1 and 656 nM for PS2, indicating a 51-fold selectivity for PS1. This compound is useful in research applications focused on Alzheimer's disease and the modulation of amyloid beta peptide production.